carbamazepine vs vorapaxar
According to this portal's Publishing Organization, this page was last reviewed in August 2026 against our methodology. Figures and extracts on this site, including tables above 1,000 rows when the corpus is that large, are the publisher's responsibility.
Side-by-side comparison of carbamazepine and vorapaxar. Data from FDA drug databases (Orange Book, NDC Directory, recalls, shortages) covering 20,000+ approved drugs, plus CMS pricing; see our methodology.
moderate Known Drug Interaction
Strong CYP3A Inducers Avoid concomitant use of ZONTIVITY with strong inducers of CYP3A (e.g., rifampin, carbamazepine, St.
Tegretol
Zontivity
Carbamazepine is a medicine used to control seizures and treat nerve pain. It works by reducing abnormal electrical activity in the brain and calming nerve signals.
Vorapaxar (Zontivity) helps prevent blood clots if you have had a heart attack or have peripheral artery disease. It works by stopping platelets in your blood from sticking together and forming clots.
Carbamazepine is used to treat certain types of seizures, including partial seizures and generalized tonic-clonic seizures. It can also treat mixed seizure patterns. Carbamazepine also treats the pain from trigeminal neuralgia, a nerve disorder that causes intense facial pain. It is also sometimes used for glossopharyngeal neuralgia.
Vorapaxar is used to lower the chance of having serious heart problems if you have a history of heart attack or peripheral artery disease (PAD). PAD is when you have narrowed arteries that reduce blood flow to your limbs. This medicine can help prevent heart death, heart attack, stroke, and the need for urgent procedures to open blocked heart arteries.
Carbamazepine is an anticonvulsant. It works by reducing the spread of seizure activity in the brain. It also stabilizes nerve impulses to reduce pain.
Vorapaxar is a PAR-1 antagonist, which means it blocks a specific receptor on platelets. This receptor, called protease-activated receptor-1 (PAR-1), normally causes platelets to clump together. By blocking PAR-1, vorapaxar helps prevent blood clots from forming.
- • Dizziness
- • Drowsiness
- • Unsteadiness
- • Nausea
- • Vomiting
- • Bleeding
- Seizure 3,609
- Drug Interaction 3,369
- Fall 3,044
- Dizziness 2,862
- Pyrexia 2,689
No adverse event reports.
Carbamazepine can cause severe skin reactions, including Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN), which can be fatal. If you are of Asian descent, you may need a blood test before starting this medicine. Carbamazepine can also cause serious blood problems like aplastic anemia and agranulocytosis. Contact your doctor right away if you develop a fever, sore throat, rash, or unusual bleeding or bruising.
Vorapaxar can cause serious bleeding, including bleeding in the brain, which can be fatal. You should not take this medicine if you have a history of stroke, transient ischemic attack (TIA), or bleeding in the brain. Also, do not take it if you have active bleeding.
Carbamazepine may harm an unborn baby. Talk to your doctor if you are pregnant or plan to become pregnant. It is not known if carbamazepine passes into breast milk, so talk to your doctor about breastfeeding.
It is not known if vorapaxar will harm an unborn baby. Talk to your doctor if you are pregnant, plan to become pregnant, or are breastfeeding.
Also Compare, Nearby Drugs
Compare carbamazepine with
How to Read This carbamazepine vs vorapaxar Comparison
carbamazepine is classified in the Anticonvulsant drug class, while vorapaxar sits within the PAR-1 Antagonist (Antiplatelet) class. Drugs from different classes work through distinct mechanisms, so a head-to-head comparison illustrates trade-offs rather than equivalence. Both drugs are prescription-only, so a licensed provider must authorize use.
Adverse event totals above are pulled from the FDA's Adverse Event Reporting System (FAERS). For these top-ranked reactions alone, carbamazepine has 15,573 submissions while vorapaxar has 0. Those figures reflect cumulative reporting volume, not per-patient risk, so older, widely dispensed drugs typically look worse on count alone. These two drugs have a known moderate interaction flagged in FDA labeling, attributed to carbamazepine speeds up how fast your body gets rid of vorapaxar, which can make the drug less effective.. Serious warnings, pregnancy guidance, and contraindications can differ even when indications overlap.
A table cannot represent individual circumstances. Data here is sourced from FDA Structured Product Labels (SPL) and FAERS, both of which update as manufacturers and clinicians submit new information. This registry does not provide medical, treatment, substitution, or medication-change directions for carbamazepine or vorapaxar.
Registry boundary: This comparison displays source-record fields and does not provide individualized medical direction.